Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 10/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.33 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.31 |
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
| ▸ | FASN | P49327 | 1/20 | 0.30 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.30 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5268022 | 0.89 | CHEK1 (0.31) | LRRK2 | |
| SCHEMBL5272531 | 0.81 | CHEK1 (0.40) | LRRK2 | |
| SCHEMBL5267152 | 0.79 | HSP90AA1 (0.38) | — | |
| SCHEMBL5267956 | 0.76 | LRRK2 (0.41) | LRRK2 | |
| SCHEMBL5266777 | 0.75 | HSP90AA1 (0.33) | — | |
| SCHEMBL5273461 | 0.74 | MET (0.35) | LRRK2ADORA2AADORA1 | |
| SCHEMBL5272249 | 0.73 | MEN1 (0.39) | IDO1 | |
| SCHEMBL5273258 | 0.73 | HSP90AA1 (0.34) | IDO1 | |
| SCHEMBL5269354 | 0.73 | HSP90AA1 (0.48) | — | |
| SCHEMBL22385981 | 0.70 | CLK4 (0.44) | MAOBIDO1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1456180-B1 | 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE | VERNALIS CAMBRIDGE LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-7247734-B2 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2007-07-24 | — | — | US | disclosed |
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2005-10-06 | — | — | US | disclosed |
| EP-1456180-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | Vernalis (Oxford) Ltd (GB) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003055860-A1 | 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER | VERNALIS (CAMBRIDGE) LIMITED (GB) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222230-A1 | 3,4-diarylpyrazoles and their use in the therapy of cancer | HSP90AB1, HSP90AA1, HSP90AB2P | LRRK2 3042/4885MAOB 4085/4885MAP4K4 2469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.